Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

934.60 +83.39 (+9.80%)
Official Closing Price Updated: 4:10 PM EDT, Apr 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Thursday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill
In today's session, there are S&P500 stocks with remarkable trading volume. ↗
Via Chartmill
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill
News headline image
Eli Lilly Raises 2026 Outlook On Strong Mounjaro And Zepbound Demand ↗
Eli Lilly beats Q1 estimates, lifts 2026 outlook as Mounjaro and Zepbound demand offsets pricing pressure and drives strong revenue growth. 
Via Benzinga
News headline image
Eli Lilly (LLY) Q1 2026 Earnings Transcript ↗
Eli Lilly (LLY) Q1 2026 Earnings Transcript 
Via The Motley Fool
Eli Lilly (NYSE:LLY) Shatters Q1 Expectations with Blowout Earnings Beat ↗
Via Chartmill
News headline image
Why Eli Lilly Stock Just Popped ↗
GLP-1 drugs turned Lilly into a powerhouse. Now it's time to write the next chapter -- in cancer. 
Via The Motley Fool
These S&P500 stocks are gapping in today's session ↗
Via Chartmill
News headline image
Eli Lilly Obliterates Sales Forecasts By $2 Billion, Shares Surge ↗
Eli Lilly stock popped early Thursday after the drugmaker crushed first-quarter sales forecasts and hiked its 2026 guidance. 
Via Investor's Business Daily
Discover the top S&P500 movers in Thursday's pre-market session. ↗
Via Chartmill
News headline image
Eli Lilly (NYSE:LLY) Delivers Strong Q1 CY2026 Numbers, Stock Soars
Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 55.5% year on year to ... 
Via StockStory
News headline image
What's the Next Big Thing After GLP-1 Drugs? CRISPR Therapeutics May Have the Answer. ↗
The biotech's candidate may treat a great number of illnesses that have one thing in common. 
Via The Motley Fool
News headline image
Eli Lilly Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts ↗
Eli Lilly & Co. (LLY) will release Q1 earnings on April 30. Analysts expect $6.79/share, up from $3.34/share last year. LLY down 2.6% on Wed. 
Via Benzinga
News headline image
Eli Lilly (LLY) Q1 Earnings: What To Expect
Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting results this Thursday before market hours. Here’s what to expect. Eli Lilly beat analyst... 
Via StockStory
News headline image
Is Eli Lilly Stock Undervalued at $870? 1 Top Wall Street Analyst Thinks So ↗
And he may be right. 
Via The Motley Fool
News headline image
Why WeightWatchers (WW) Shares Are Trading Lower Today
What Happened? Shares of personal wellness company WeightWatchers (NASDAQ:WW) fell 5.3% in the afternoon session after the company announced its intention to... 
Via StockStory
Topics Initial Public Offering
News headline image
Amazon Takes a Bite Out of Hims: What Its GLP-1 Entrance Means ↗
Via MarketBeat
News headline image
Is This Deal a Game Changer for Novo Nordisk? ↗
The drugmaker is getting on the AI train in ways that could move the needle down the road. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Forget Weight Loss Drugs: Here's An Even Better Reason to Invest in Eli Lilly ↗
Eli Lilly has more to offer than some investors realize. 
Via The Motley Fool
News headline image
Should You Buy HIMS Stock Following Friday's Rally?
Hims & Hers stock rallied on Friday on a major regulatory update and bullish analyst note. Here’s how high HIMS shares could realistically fly through the end of 2026. 
Via Barchart.com
News headline image
Should You Buy the Dip in Eli Lilly Stock Today?
Eli Lilly shares sink as data shows Foundayo trailing Novo’s oral Wegovy. But there’s reason to consider buying LLY shares on the dip today. 
Via Barchart.com
News headline image
Is Bristol Myers Squibb the Best Bargain in Big Pharma? ↗
This pharma stock is cheap for a reason. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Is SpaceX Really Worth $1.75 Trillion -- or Is That Actually Too Low? ↗
This space stock could literally go "to the moon." 
Via The Motley Fool
Topics Artificial Intelligence Initial Public Offering
News headline image
Nuclear Is Back in a Big Way. Here Are 2 Stocks to Consider. ↗
With more focus on nuclear energy, companies connected to nuclear power could be strong long-term investments. 
Via The Motley Fool
News headline image
This Obesity Stock Could More Than Double Over the Next 12 Months, According to Wall Street ↗
Most investors currently see the glass on this stock as being half-empty. Analysts, however, still view the glass as at least half-full. 
Via The Motley Fool
News headline image
Should You Add a Healthcare Stock to Your Portfolio This Month? And Should It Be Eli Lilly (LLY)? ↗
Eli Lilly is a giant in the weight-loss drug realm, and it's aiming to grow more. 
Via The Motley Fool
News headline image
Looking to Buy the Tech Turnaround? This Low-Cost Vanguard ETF Might Be Your Best Entry Point. ↗
You get the upside of the sector, while minimizing some of the risks. 
Via The Motley Fool
Topics Artificial Intelligence ETFs
News headline image
Is This Tech Giant the Next Potential Winner in the GLP-1 Weight Loss Boom? ↗
The weight loss drug market may reach almost $100 billion in a few years. 
Via The Motley Fool
News headline image
Why Eli Lilly Stock Flopped on Friday ↗
High hopes for a freshly approved drug might not be realized, if early data is any indication. 
Via The Motley Fool
News headline image
Why Eli Lilly (LLY) Shares Are Trading Lower Today
What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 3.6% in the afternoon session after disappointing weekly prescription number... 
Via StockStory
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.